Annals of dermatology最新文献

{"title":"Primary Cutaneous CD30+ Lymphoproliferative Disorders in South Korea: A Nationwide, Multi-Center, Retrospective, Clinical, and Prognostic Study.","authors":"Woo Jin Lee, Sook Jung Yun, Joon Min Jung, Joo Yeon Ko, Kwang Ho Kim, Dong Hyun Kim, Myung Hwa Kim, You Chan Kim, Jung Eun Kim, Chan-Ho Na, Je-Ho Mun, Jong Bin Park, Ji-Hye Park, Hai-Jin Park, Dong Hoon Shin, Jeonghyun Shin, Sang Ho Oh, Seok-Kweon Yun, Dongyoun Lee, Seok-Jong Lee, Seung Ho Lee, Young Bok Lee, Soyun Cho, Sooyeon Choi, Jae Eun Choi, Mi Woo Lee","doi":"10.5021/ad.24.120","DOIUrl":"10.5021/ad.24.120","url":null,"abstract":"<p><strong>Background: </strong>Primary cutaneous CD30+ lymphoproliferative disorders (pcCD30-LPDs) are a diseases with various clinical and prognostic characteristics.</p><p><strong>Objective: </strong>Increasing our knowledge of the clinical characteristics of pcCD30-LPDs and identifying potential prognostic variables in an Asian population.</p><p><strong>Methods: </strong>Clinicopathological features and survival data of pcCD30-LPD cases obtained from 22 hospitals in South Korea were examined.</p><p><strong>Results: </strong>A total of 413 cases of pcCD30-LPDs (lymphomatoid papulosis [LYP], n=237; primary cutaneous anaplastic large cell lymphoma [C-ALCL], n=176) were included. Ninety percent of LYP patients and roughly 50% of C-ALCL patients presented with multiple skin lesions. Both LYP and C-ALCL affected the lower limbs most frequently. Multiplicity and advanced T stage of LYP lesions were associated with a chronic course longer than 6 months. Clinical morphology with patch lesions and elevated serum lactate dehydrogenase were significantly associated with LPDs during follow-up in LYP patients. Extracutaneous involvement of C-ALCL occurred in 13.2% of patients. Lesions larger than 5 cm and increased serum lactate dehydrogenase were associated with a poor prognosis in C-ALCL. The survival of patients with C-ALCL was unaffected by the anatomical locations of skin lesions or other pathological factors.</p><p><strong>Conclusion: </strong>The multiplicity or size of skin lesions was associated with a chronic course of LYP and survival among patients with C-ALCL.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"75-85"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative Tumor Density of Soft-Tissue Sarcoma in Korean Population: An Institutional Review.","authors":"Bo Bin Cha, Jung Yup Kim, Won-Serk Kim, Ga-Young Lee, Young-Jun Choi","doi":"10.5021/ad.23.122","DOIUrl":"10.5021/ad.23.122","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive studies on the tumor burden of soft-tissue sarcoma (STS) by anatomical site are lacking in Asian populations.</p><p><strong>Objective: </strong>To investigate the anatomical distribution of STS via relative tumor density (RTD) in a Korean cohort.</p><p><strong>Methods: </strong>The RTDs of patients with STS at a single-institution from 2007-2022 were retrospectively analyzed. To describe the STS locations, the body was divided into 4 anatomical sites, and the RTD of each was calculated to the compare topographic tumor burden.</p><p><strong>Results: </strong>Fifty-nine cases in 58 individuals, 35 male (60.3%) and 23 female (39.7%), with a mean age of 56.5±20.4 were analyzed. Overall, the most frequent STS site was the lower extremity (LE, n=22, 37.3%), and the highest RTD was in the head and neck (H&N, 2.44; 95% confidence interval, 1.39-3.77). Dermatofibrosarcoma protuberans (DFSP), Kaposi's sarcoma (KS), and angiosarcoma (AS) accounted for 76.3% of all the cases. DFSP, KS, and AS showed significantly higher RTD on the trunk (2.55, <i>p</i>=0.025), LE (3.88, <i>p</i><0.001), and H&N (7.42, <i>p</i><0.001), respectively, than elsewhere.</p><p><strong>Conclusion: </strong>Each STS displays topographic variability and produces different topographic tumor burdens by body site in an Asian population.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"96-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965874/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice.","authors":"Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.5021/ad.24.127","DOIUrl":"10.5021/ad.24.127","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) is a chronic eczematous disorder characterized by intense itchiness. Systemic therapies for AD include Janus kinase (JAK) inhibitors and various biological agents. The effects of transitioning from the JAK1 inhibitor, upadacitinib, to the anti-interleukin 13 antibody, tralokinumab, remain unclear.</p><p><strong>Objective: </strong>This study evaluated the transition from 15 mg of upadacitinib to tralokinumab in patients with moderate-to-severe AD.</p><p><strong>Methods: </strong>This analysis included 20 patients who switched from 15 mg of upadacitinib to tralokinumab due to an inadequate response or adverse events (AEs). We assessed the total and regional eczema area and severity index (EASI), which included assessments of the head and neck, trunk, and upper and lower limbs, along with erythema, edema/papulation, excoriation, lichenification, and the peak pruritus numerical-rating scale (PP-NRS), initially (start of 15 mg of upadacitinib), at the transition point (week 0), and during follow-up at weeks 4 and 12.</p><p><strong>Results: </strong>The EASI, EASI of the four anatomical regions, and EASI of the four clinical manifestations significantly declined from baseline at weeks 4 and 12, with no substantial reductions from week 0. The PP-NRS score notably decreased from baseline at week 4. Achieving EASI of 50 and 75 improved post-switching.</p><p><strong>Conclusion: </strong>Transitioning to tralokinumab substantially alleviated rash in patients with AD who experienced suboptimal responses or AEs to 15 mg of upadacitinib.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"86-95"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy, Safety and Longevity of Biologic Treatments in Pediatric and Adult Psoriasis Patients: A Comparative Multi-Center, Real-Life Study.","authors":"Özlem Akın Çakıcı, Zeynep Topkarcı, Begüm Yurtsever Güneş, Nahide Onsun, Dilek Seçkin, Tülin Ergun","doi":"10.5021/ad.24.057","DOIUrl":"10.5021/ad.24.057","url":null,"abstract":"<p><strong>Background: </strong>Evidence on the effectiveness, long-term safety and longevity of biologic therapies in pediatric psoriasis patients is sparse.</p><p><strong>Objective: </strong>This study aims to compares the efficacy, safety and drug survival (DS) rates of etanercept (ETA), adalimumab (ADA), infliximab (INF), ustekinumab (UST), secukinumab (SEC) and ixekizumab (IXE) in pediatric and adult psoriasis patients.</p><p><strong>Methods: </strong>293 biologic treatment cycles of 198 patients (62 pediatric and 136 adult) from three academic psoriasis referral centres were analysed.</p><p><strong>Results: </strong>The following were the Psoriasis Area and Severity Index 90 response scores of pediatric and adult psoriasis patients, respectively: ETA, 42.3% vs. 34.6%; ADA, 53.8% vs. 59.8%; INF, 33.3% vs. 33.3%; UST, 76.5% vs. 56.8%; SEC, 60% vs. 60%; and IXE, 50% vs. 87.5%. The differences of responses between the two groups were statistically insignificant (<i>p</i>>0.05). ETA had the longest mean DS time in the pediatric group but it was related to a significantly shorter DS in pediatric patients than in adults (pediatrics: 30.58 [18.64-42.52] months vs. adults: 72.34 [54.70-89.99] months; <i>p</i>=0.025). ADA had the longest mean DS time in the adult group with 101.28 [84.88-117.68] months. All treatments had favorable safety profiles. No specific severe adverse effects necessitating treatment discontinuation were observed in pediatric patients.</p><p><strong>Conclusion: </strong>Although responses to ETA and UST were numerically better among children, the difference was insignificant. The DS rates in each group were comparable, and no specific safety signals, limiting the long-term use of these agents, were detected in the pediatric group.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"114-121"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965878/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143756563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Clinicopathologic Feature and Survival Analysis of Cutaneous Angiosarcoma: A Single Tertiary Center Study.","authors":"Yeon Joo Jung, Joonho Shim, Se Jin Oh, Jong Hee Lee, Dong-Youn Lee, Jihye Park","doi":"10.5021/ad.24.086","DOIUrl":"10.5021/ad.24.086","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous angiosarcoma, a rare malignant tumor, is associated with high mortality and poor prognosis.</p><p><strong>Objective: </strong>This study aimed to analyze the clinicopathologic features of cutaneous angiosarcoma and identify the prognostic factors influencing survival.</p><p><strong>Methods: </strong>Medical records of patients diagnosed with cutaneous angiosarcoma between January 1995 and March 2023 were retrospectively reviewed. Demographic data, clinicopathologic features, and treatment modalities were analyzed to evaluate the correlation with overall survival (OS) and progression-free survival (PFS). A total of 70 patients were included in the study.</p><p><strong>Results: </strong>Their mean age at diagnosis was 71 years (range, 41-91 years). Of them, 57 (81.4%) were males. Five-year OS and PFS rates were 29.0% and 10.7%, respectively. In univariate analysis, a mass in the frontal area of the scalp showed significant associations with poorer PFS (hazard ratio [HR], 1.95; 95% confidence interval [CI], 1.07-3.55; <i>p</i>=0.029) and poorer OS (HR, 2.42; 95% CI, 1.22-4.80; <i>p</i>=0.011). Mass size exceeding 3 cm had a notable impact on PFS (HR, 3.41; 95% CI, 1.32-8.82; <i>p</i>=0.011) and remained a significant independent adverse prognosticator in multivariate analysis (HR, 4.55; 95% CI, 1.22-16.99; <i>p</i>=0.024).</p><p><strong>Conclusion: </strong>Cutaneous angiosarcoma is characterized by an unfavorable prognosis, with a larger mass size identified as an independent prognostic factor.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"68-74"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Additional Use of Hyaluronic Acid-Based Dissolving Microneedle Patches to Treat Psoriatic Plaques: A Randomized Controlled Trial.","authors":"Hyun Jeong Ju, Ji Yoon Kim, Do Hyeon Jeong, Moon-Su Lee, Gyong Moon Kim, Jung Min Bae, Ji Hae Lee","doi":"10.5021/ad.24.024","DOIUrl":"10.5021/ad.24.024","url":null,"abstract":"<p><strong>Background: </strong>Despite advances in systemic targeted therapies, topical agents remain the primary treatment for localized psoriasis. However, their therapeutic effects are often delayed and unsatisfactory. The dissolving microneedle (DMN) patch, a novel transdermal drug delivery system, enhances the absorption of topical agents through micro-channels.</p><p><strong>Objective: </strong>To evaluate the efficacy of DMN patches in enhancing drug delivery and improving clinical outcomes in psoriatic plaques.</p><p><strong>Methods: </strong>A prospective, randomized, split-body study was conducted to verify the efficacy of additional use of DMN patches after topical agent application in psoriasis treatment. Patients with mild psoriasis were enrolled and 6 paired lesions per patient were randomized into 3 groups: ointment-only, ointment-with-no needle patch, and ointment-with-DMN patch. Lesions were treated with a topical agent (betamethasone and calcipotriol) once daily for 2 weeks. Modified psoriasis area and severity index (mPASI) scores were measured weekly. <i>In vitro</i> and <i>ex vivo</i> experiments were performed to confirm micro-channel formation, microneedle dissolution, and drug penetration enhancement.</p><p><strong>Results: </strong>A total of 132 paired lesions from 22 patients were analyzed. The ointment-with-DMN patch group showed significantly improved mPASI scores (80.4%±20.5%; 5.42→1.06) compared to the ointment-with-no needle patch (64.6%±33.0%; 4.94→1.68) (<i>p</i><0.05) and ointment-only groups (55.5%±31.4%; 5.00→2.15) (<i>p</i><0.001). <i>In vitro</i> studies demonstrated 2.1-fold enhanced drug delivery with DMN patches, while <i>ex vivo</i> histological analysis confirmed micro-channel formation. No adverse events, including infection or psoriasis exacerbation, were observed.</p><p><strong>Conclusion: </strong>The DMN patch is an effective adjunctive tool that enhances transdermal drug delivery and improves therapeutic outcomes in psoriatic plaques, particularly those refractory to topical agents.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02955576.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"105-113"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Air Pollution and Skin Diseases.","authors":"Hye Sung Han, Joon Seok, Kui Young Park","doi":"10.5021/ad.24.159","DOIUrl":"10.5021/ad.24.159","url":null,"abstract":"<p><p>Air pollution is a widespread environmental issue, with substantial global implications for human health. Recent epidemiological studies have shown that exposure to air pollution exacerbates various inflammatory skin conditions, including atopic dermatitis, psoriasis, or acne. Furthermore, air pollutants are associated with accelerated skin aging, hair loss, and skin cancer. The aim of this review is to elucidate the current understanding of the impact of air pollution on skin health, emphasizing the underlying mechanisms involved and existing therapeutic and cosmetic interventions available to prevent or mitigate these effects. A pivotal factor in the harmful effects of air pollution is the formation of reactive oxygen species and the resulting oxidative stress. The aryl hydrocarbon receptor signaling pathway also substantially contributes to mediating the effects of air pollutants on various skin conditions. Moreover, air pollutants can disrupt the skin barrier function and trigger inflammation. Consequently, antioxidant and anti-inflammatory therapies, along with treatments designed to restore the skin barrier function, have the potential to mitigate the adverse effects of air pollutants on skin health.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 2","pages":"53-67"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143757261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a Novel Three-immunogene Diagnostic Signature for Alopecia Areata.","authors":"Xiuwen Chen, Wenzi Liang, Changmin Lin, Yike Lin","doi":"10.5021/ad.24.053","DOIUrl":"10.5021/ad.24.053","url":null,"abstract":"<p><strong>Background: </strong>Autoimmune mechanisms have important roles in the pathogenesis of alopecia areata (AA).</p><p><strong>Objective: </strong>This study aimed to evaluate the exact biological and clinical importance of immunogenes in AA patients using bioinformatic methods.</p><p><strong>Methods: </strong>Five AA scalp gene expression profiles were obtained from the Gene Expression Omnibus database. Differentially-expressed genes (DEGs) between AA and control groups were identified. An immune-related gene diagnostic signature (IRGDS) was established by protein-protein interaction network analysis, least absolute shrinkage and selection operator and logistic regression analysis.</p><p><strong>Results: </strong>A total of 102 immune-related DEGs were identified. We developed an IRGDS composed of CD8A, CSF1R and CXCL10 for AA molecular pathological assessment and diagnosis (area under the receiver operating characteristic curve [AUC]=0.962). We also validated the diagnostic value of the IRGDS in an external cohort (AUC=0.955). Patients with high IRGDS scores presented with a higher abundance of immune cell infiltration and expression of genes associated with immune recruitment and immune activation, suggesting adverse biological alterations.</p><p><strong>Conclusion: </strong>In our study, an IRGDS model with accurately diagnostic capacity for AA was established, and biological alterations were deciphered in AA. The IRGDS may be used as an auxiliary diagnostic marker for AA.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 1","pages":"22-31"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 Consensus Korean Diagnostic Criteria for Atopic Dermatitis.","authors":"Ji Hyun Lee, Sul Hee Lee, Youin Bae, Young Bok Lee, Yong Hyun Jang, Jiyoung Ahn, Joo Yeon Ko, Hyun-Chang Ko, Hye One Kim, Chan Ho Na, Young-Joon Seo, Min Kyung Shin, Yu Ri Woo, Bark Lyn Lew, Dong Hun Lee, Sang Eun Lee, Jiehyun Jeon, Sun Young Choi, Tae Young Han, Yang Won Lee, Sang Wook Son, Young Lip Park","doi":"10.5021/ad.24.049","DOIUrl":"10.5021/ad.24.049","url":null,"abstract":"<p><strong>Background: </strong>In 2006, the Korean Atopic Dermatitis Association (KADA) working group released the diagnostic criteria for Korean atopic dermatitis (AD). Recently, more simplified, and practical AD diagnostic criteria have been proposed.</p><p><strong>Objective: </strong>Based on updated criteria and experience, we studied to develop and share a consensus on diagnostic criteria for AD in Koreans.</p><p><strong>Materials and methods: </strong>For the diagnostic criteria, a questionnaire was constructed by searching the English-language literature in MEDLINE and the Cochrane Database of Systematic Reviews. A modified Delphi method composed of 3 rounds of email questionnaires was adopted for the consensus process. Fifty-four KADA council members participated in the 3 rounds of votes and expert consensus recommendations were established.</p><p><strong>Results: </strong>Diagnostic criteria for AD include pruritus, eczema with age-specific pattern, and chronic or relapsing history. Diagnostic aids for AD encompass xerosis, immunoglobulin E reactivity, hand-foot eczema, periorbital changes, periauricular changes, perioral changes, nipple eczema, perifollicular accentuation, and personal or family history of atopy.</p><p><strong>Conclusion: </strong>This study streamlined and updated the diagnostic criteria for AD in Korea, making them more practicable for use in real-world clinical field.</p>","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 1","pages":"12-21"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791022/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hands and Wrists Are the Best Sites for Diagnosing Scabies Through Dermoscopy and Microscopy.","authors":"Hyun-Chul Chung, Ye-Ji Kim, Eun-Ji Chun, Sang-Seok Kim, Chul-Woo Kim","doi":"10.5021/ad.23.101","DOIUrl":"10.5021/ad.23.101","url":null,"abstract":"","PeriodicalId":94298,"journal":{"name":"Annals of dermatology","volume":"37 1","pages":"46-48"},"PeriodicalIF":0.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11791019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}